REXAHN PHARMACEUTICALS, INC. REXN Income Statement

Rexahn pharmaceuticals, inc. (REXN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
0	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	-	-	-	18	0	0	0
Expenses:
General and administrative
5,298	5,738	6,421	7,067	7,296	7,428	6,826	6,605	6,775	6,639	6,838	6,683	6,619	6,324	5,941	6,076	5,985	6,115	6,298	6,060	6,283	6,253	6,343	5,959	5,009	4,725	3,643	3,311	3,195	2,713	2,807	2,981	3,166	3,547	4,372	5,403	0	0	0
Research and development
3,691	5,476	7,752	9,508	11,292	13,109	13,642	13,399	12,511	10,715	9,536	9,190	8,882	10,089	10,920	11,725	12,723	12,148	11,450	10,171	8,637	7,015	5,791	4,748	3,972	3,253	2,524	2,809	2,902	3,392	4,612	5,918	10,317	11,992	11,178	10,134	0	0	0
Patent fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	486	508	465	431	474	550	576	546	497	361	0	0	0
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38	39	40	42	42	41	41	45	46	48	0	0	0
Total Expenses
8,990	11,215	14,173	16,576	18,589	20,537	20,469	20,004	19,287	17,354	16,375	15,873	15,502	16,413	16,861	17,802	18,709	18,263	17,748	16,231	14,920	13,269	11,749	10,431	8,835	7,978	6,693	6,668	6,604	6,579	7,936	9,492	14,101	16,131	16,094	15,947	0	0	0
Loss from Operations
-7,840	-11,215	-14,173	-16,576	-18,589	-20,537	-20,469	-20,004	-19,287	-17,354	-16,375	-15,873	-15,502	-16,413	-16,861	-17,802	-18,709	-18,263	-17,748	-16,231	-14,920	-13,269	-11,749	-10,431	-8,835	-7,978	-6,693	-6,668	-6,604	-6,579	-7,936	-9,492	-14,101	-16,131	-16,094	-15,928	0	0	0
Other Income
Realized loss on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	-3	-3	0	0	0
Interest income
266	313	312	289	259	254	270	275	250	207	170	135	121	118	105	103	101	103	110	121	132	133	119	98	71	49	38	32	24	21	25	38	73	109	150	157	0	0	0
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other income
-	-	-	-	-	368	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Unrealized (loss) gain on fair value of warrants
-694	-2,265	-3,977	-3,024	-3,692	-5,546	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on fair value of warrants
-	-	-	-	-	-	-	-	-	-	-7,459	-9,612	-13,015	5,529	4,549	5,141	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain on fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	7,103	8,523	13,395	1,365	-263	714	-1,294	-663	-2,129	-5,191	-4,984	-4,778	-4,530	-2,353	0	0	0
Unrealized gain on fair value of put feature on common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Financing expense
-	-	-	-	-	-	-	-	-	-	-	0	-	313	0	0	0	-	-	-	-	206	318	0	0	-	0	-	-	-	-	-	-	97	97	277	0	0	0
Beneficial conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Total Other (Loss) Income
960	2,579	4,290	3,313	3,952	6,169	5,625	9,461	13,528	-7,939	-5,851	-8,182	-11,266	7,106	5,227	5,009	4,447	3,878	4,006	4,610	6,728	-5,252	-7,282	-8,835	-13,733	-1,520	-142	-1,014	987	352	2,154	5,230	5,053	4,786	4,579	2,285	0	0	0
Net Loss Before Provision for Income Taxes
-6,879	-8,635	-9,883	-13,262	-14,636	-14,368	-14,844	-10,543	-5,758	-25,294	-22,227	-24,056	-26,769	-9,307	-11,634	-12,793	-14,261	-14,384	-13,742	-11,621	-8,192	-18,521	-19,031	-19,266	-22,569	-9,499	-6,835	-7,683	-5,616	-6,226	-5,781	-4,262	-9,048	-11,344	-11,515	-13,643	0	0	0
Provision for Income Taxes
-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	-	-	-	0	0	0	0
Net Loss
-6,879	-8,635	-9,883	-13,262	-14,636	-14,368	-14,844	-10,543	-5,758	-25,294	-22,227	-24,056	-26,769	-9,307	-11,634	-12,793	-14,261	-14,384	-13,742	-11,621	-8,192	-18,521	-19,031	-19,266	-22,569	-9,499	-6,835	-7,683	-5,616	-6,226	-5,781	-4,262	-9,048	-11,344	-11,515	-13,643	0	0	0
Net Income (Loss) per share, basic
-	-	-	-	-	-	-	-	-	-	-	0.04	-	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) per share, diluted
-	-	-	-	-	-	-	-	-	-	-	0.03	-	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average number of shares outstanding, basic
-	-	-	-	-	-	-	-	-	-	-	26,001	-	-	-	21,318	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average number of shares outstanding, diluted
-	-	-	-	-	-	-	-	-	-	-	28,265	-	-	-	21,318	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share, basic and diluted
-0.15	-0.46	-0.49	-0.61	-0.62	-0.99	-2.02	-1.45	-0.79	-	-0.04	-	-0.91	-	-0.13	-	-0.02	-0.73	-0.02	-0.02	-0.02	-0.01	-0.01	0.00	-0.09	-0.01	-0.02	-0.03	-0.01	0.00	-0.03	-0.01	-0.02	0.01	-0.02	-0.06	-0.05	0.00	-0.05
Weighted average number of shares outstanding, basic and diluted
4,019	4,022	4,019	4,019	3,779	3,031	2,641	2,640	2,639	-	28,459	-	23,851	-	21,644	-	202,586	-466,693	180,701	179,849	179,097	178,365	178,219	177,729	170,112	145,154	130,466	119,547	119,428	102,515	95,345	95,345	95,345	95,464	95,240	95,237	86,251	-	-
Weighted Average number of shares outstanding, basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83,063	74,247